Pacira BioSciences Inc’s recently made public that its Officer GAUGLER DARYL acquired Company’s shares for reported $11625.0 on Mar 06 ’25. In the deal valued at $23.25 per share,500 shares were bought.
Then, SLONIN JONATHAN sold 879 shares, generating $16,174 in total proceeds. Upon selling the shares at $18.40, the Chief Medical Officer now owns 93,444 shares.
Before that, SLONIN JONATHAN bought 879 shares. Pacira BioSciences Inc shares valued at $16,174 were divested by the Officer at a price of $18.40 per share.
Truist upgraded its Pacira BioSciences Inc [PCRX] rating to a Hold from a a Sell in a research note published on January 30, 2025; the price target was increased to $25 from $8. A number of analysts have revised their coverage, including Truist’s analysts, who decreased its forecast for the stock in mid August from “a Buy” to “a Sell”. RBC Capital Mkts also remained covering PCRX and has decreased its forecast on August 12, 2024 with a “Sector perform” recommendation from previously “an Outperform” rating. Raymond James revised its rating on August 12, 2024. It rated PCRX as “a Mkt perform” which previously was an “an Outperform”.
Price Performance Review of PCRX
On Tuesday, Pacira BioSciences Inc [NASDAQ:PCRX] saw its stock jump 2.29% to $26.75. Over the last five days, the stock has gained 14.32%. Pacira BioSciences Inc shares have risen nearly 41.99% since the year began. Nevertheless, the stocks have fallen -15.11% over the past one year. While a 52-week high of $31.64 was reached on 04/08/25, a 52-week low of $11.16 was recorded on 01/06/25. SMA at 50 days reached $24.87, while 200 days put it at $20.27.
Levels Of Support And Resistance For PCRX Stock
The 24-hour chart illustrates a support level at 26.24, which if violated will result in even more drops to 25.72. On the upside, there is a resistance level at 27.05. A further resistance level may holdings at 27.34. The Relative Strength Index (RSI) on the 14-day chart is 58.92, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.78, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 13.49%. Stochastics %K at 75.05% indicates the stock is a holding.
